Hexane fraction of adlay (Coix lachryma-jobi L.) testa ethanolic extract inhibits human uterine sarcoma cancer cells growth and chemosensitizes human uterine sarcoma cells to doxorubicin

Chih Chao Chang, Ling Hui Huang, Wenchang Chiang, Shih Min Hsia

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Background: Cancer has remained among the top ten causes of death in Taiwan since 1982. Uterine sarcoma is a rare gynecologic cancer, and chemotherapy is one type of cancer treatment. Doxorubicin (Dox) is widely used for treating several cancers, including uterine sarcoma, however, multidrug resistance (MDR) is a major clinical problem and a critical cause of treatment failure. The ethanolic extracts of adlay testa (ATE) exhibited significant anticancer activities against many cancer types. Purpose: In this study we investigated the antitumor effects of the hexane fraction of the adlay testa ethanolic extracts (ATE-Hex) on the human uterine sarcoma cancer cell line MES-SA, as well as on the multidrug-resistant human uterine sarcoma cancer cell line MES-SA/Dx5. Methods: The MTT assay was performed to assess the effects of the extracts of different parts of the adlay on the proliferation of human uterine sarcoma cells (MES-SA and MES-SA/Dx5) and human uterine smooth muscle cells (HUtSMCs). To determine whether ATE-Hex has a chemosensitizing effect on drug-resistant uterine sarcoma cells, the MTT assay was performed to examine the synergistic effects of ATE-Hex, the chemotherapeutic drug Dox alone, and in combination. Rhodamine accumulation was analyzed using fluorescence detection. Apoptotic cells were analyzed via flow cytometry. In addition, employing a flame ionization detector (GC/FID) gas chromatography was also developed as the analysis platform for ATE-Hex. Results: The results demonstrated that ATE-Hex exhibited the best effects of inhibition on MES-SA and MES-SA/Dx5 cells. Co-treatment of ATE-Hex and Dox could synergistically inhibit the proliferation of cancer cells. ATE-Hex reduced the rhodamine efflux in MES-SA/Dx5 cells, indicating that ATE-Hex could reduce the expression of P-gp. In addition, our results showed that treatment with ATE-Hex alone or in combination with Dox significantly inhibited the growth of cancer cells and induced apoptosis by increasing the sub-G1 phase and poly(ADP-ribose) polymerase (PARP) being cleaved. Flow cytometry revealed that ATE-Hex induced apoptosis. Conclusion: These results suggest that ATE-Hex can inhibit human uterine sarcoma cancer cells by inducing apoptosis and increasing the chemosensitivity of the multidrug-resistant human uterine sarcoma cancer cell MES-SA/Dx5 to Dox. Furthermore, the combination of ATE-Hex and Dox could decrease MDR and increase the synergistic effect.

Original languageEnglish
Pages (from-to)69-80
Number of pages12
JournalPhytomedicine
Volume47
DOIs
Publication statusPublished - Aug 1 2018

Keywords

  • Adlay testa
  • Doxorubicin
  • HUtSMCs
  • MES-SA
  • MES-SA/Dx5
  • Multidrug resistance
  • Humans
  • Apoptosis/drug effects
  • Sarcoma/drug therapy
  • Drug Resistance, Neoplasm/drug effects
  • Uterine Neoplasms/drug therapy
  • Cell Cycle/drug effects
  • Hexanes
  • Drug Resistance, Multiple/drug effects
  • Taiwan
  • Cell Line, Tumor
  • Female
  • Poly (ADP-Ribose) Polymerase-1/metabolism
  • Cell Proliferation/drug effects
  • Coix/chemistry
  • Doxorubicin/pharmacology
  • Plant Extracts/pharmacology

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine
  • Complementary and alternative medicine
  • Pharmacology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Hexane fraction of adlay (Coix lachryma-jobi L.) testa ethanolic extract inhibits human uterine sarcoma cancer cells growth and chemosensitizes human uterine sarcoma cells to doxorubicin'. Together they form a unique fingerprint.

Cite this